| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
Flosulide manufacturers
- Flosulide
-
- $2800.00
-
2026-04-21
- CAS:80937-31-1
- Purity:
- Supply Ability: 10g
- Flosulide
-
- $2800.00
-
2025-07-18
- CAS:80937-31-1
- Purity:
- Supply Ability: 10g
|
| | Flosulide Basic information |
| Product Name: | Flosulide | | Synonyms: | CGP-28238;CGP-28328;N-[[6-(2,4-Difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden]-5-yl]methanesulfonamide;Flosulide;N-[1-Oxo-6-(2,4-difluorophenoxy)indan-5-yl]methanesulfonamide;ZK-38997;Methanesulfonamide, N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]- | | CAS: | 80937-31-1 | | MF: | C16H13F2NO4S | | MW: | 353.344 | | EINECS: | | | Product Categories: | | | Mol File: | 80937-31-1.mol |  |
| | Flosulide Chemical Properties |
| Melting point | 156 °C(Solv: ethanol (64-17-5)) | | Boiling point | 446.9±55.0 °C(Predicted) | | density | 1.506±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 6.95±0.20(Predicted) |
| | Flosulide Usage And Synthesis |
| Uses | Flosulide is a potent and selective COX-2 inhibitor, used for the treatment for inflammatory diseases. | | in vivo | In normovolemic rats, flosulide increases renal plasma flow (RPF) and and glomerular filtration rate (GFR). In hypovolemic rats, flosulide (5-25 mg/kg) reduces RPF and GFR. Flosulide at 5 mg/kg reduces 6-keto-PGF1alpha whereas at 25 mg/kg and after indomethacin at 10 mg/kg a fall in 6-keto-PGF1alpha and TXB2 appeares[1]. Flosulide (0.75 mg/day) significantly reduces proteinuria as compared to aspirin treatment. Plasma protein and albumin levels are significantly lower in the aspirin-treated group than in flosulide-treated rats[3]. | | IC 50 | COX-2 | | References | [1] Turull A, et al. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats. Inflammation. 2001 Apr;25(2):119-28. DOI:10.1023/a:1007122706770
[2] Zimmermann KC, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999 Jan 1;59(1):198-204. PMID:9892207
[3] Heise G, et al. Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Nephron. 1998 Oct;80(2):220-6. DOI:10.1159/000045171 |
| | Flosulide Preparation Products And Raw materials |
|